# Effect of Glucose Degradation Products (GDP) on Endothelial Dysfunction

> **NCT01315314** · PHASE4 · COMPLETED · sponsor: **Kyungpook National University Hospital** · enrollment: 146 (actual)

## Conditions studied

- Kidney Failure, Chronic
- Disorders Associated With Peritoneal Dialysis

## Interventions

- **DRUG:** Balance, Fresenius Medical Care, Germany

## Key facts

- **NCT ID:** NCT01315314
- **Lead sponsor:** Kyungpook National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2011-03-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01315314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01315314, "Effect of Glucose Degradation Products (GDP) on Endothelial Dysfunction". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01315314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*